标题:Therapeutic advancement of chronic lymphocytic leukemia
作者:Lu, Kang; Wang, Xin
作者机构:[Lu, Kang; Wang, Xin] Shandong Univ, Prov Hosp, Dept Hematol, Jinan 250021, Shandong, Peoples R China.; [Wang, Xin] Shandong Univ, Sch Med, Dept Dia 更多
通讯作者:Wang, X
通讯作者地址:[Wang, X]Shandong Univ, Prov Hosp, Dept Hematol, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.
来源:JOURNAL OF HEMATOLOGY & ONCOLOGY
出版年:2012
卷:5
DOI:10.1186/1756-8722-5-55
关键词:Chronic lymphocytic leukemia; Treatment; Monoclonal antibodies
摘要:Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This article reviews the ongoing clinical advances in the treatment of CLL in both previously untreated and relapsed disease and focuses on the benefit of different therapeutic strategies, the most effective therapy combinations and the potential activity of novel agents. Novel agents and combination therapies have been investigated by several studies in both the upfront and relapsed setting, particularly for patients with 17p deletion, TP53 mutation and fludarabine-refractory CLL. While these agents and combination therapies have improved initial response rates, ongoing studies are continued to determine and improve the efficacy and safety. Despite advancements in the treatment of CLL have led to high response rates, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option and reduced-intensity conditioning (RIC) allo-HSCT must be strongly considered whenever feasible. As such, ongoing studies of these agents and other novel approaches in clinical development are needed to expand and improve treatment options for CLL patients.
收录类别:SCOPUS;SCIE
WOS核心被引频次:23
Scopus被引频次:25
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866174279&doi=10.1186%2f1756-8722-5-55&partnerID=40&md5=e0f547d402b8503f34c53a211f87e269
TOP